BioSpace News Archive

Daewoong Pharmaceutical announced that it had signed a Global License Agreement for its autoimmune disease drug candidate DWP213388 with Vitalli Bio, a US biotechnology company, on April 28.

Otsuka America Pharmaceutical, Inc. and Lundbeck announce the U.S. Food and Drug Administration has approved the New Drug Application for ABILIFY ASIMTUFII® extended-release injectable suspension for intramuscular use, a once-every-two-months injection for the treatment of schizophrenia in adults or for maintenance monotherapy treatment of bipolar I disorder in adults.

OncoNano Medicine, Inc. today announced an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023, taking place June 2-6, 2023 at McCormick Place, Chicago, Illinois.

A new antidepressant drug candidate being developed by researchers at Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) is said to have mechanistic activity and therapeutic features that set it apart from almost all of the currently approved antidepressants in the U.S.

The Board of Directors of McKesson Corporation (NYSE:MCK) yesterday declared a regular dividend of 54 cents per share of common stock.

Takeda today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its Biologics License Application (BLA) resubmission for the investigational subcutaneous (SC) administration of Entyvio® (vedolizumab) for maintenance therapy in adults with moderately to severely active ulcerative colitis (UC) after induction therapy with Entyvio intravenous.

Tavros Therapeutics, Inc. and OpenBench, Inc. today announced the companies have entered into a collaboration agreement to discover small molecule modulators of up to five oncology targets across an initial 18-month term.

Prelude Therapeutics Incorporated today announced that company executives will participate in three upcoming healthcare investment conferences.

Angel Medical Systems Inc., a company focused on improving long-term management of high-risk coronary disease in patients who have survived one or more heart attacks, announced it has changed its corporate name to Avertix Medical Inc., and appointed Tim Moran as President and Chief Executive Officer and Philip Tom as Executive Vice President and Chief Financial Officer, effective immediately.

Nektar Therapeutics (Nasdaq: NKTR) today announced that it will be regaining the full rights to REZPEG from Eli Lilly and Company.